{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:55:42Z","timestamp":1790193342694,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00115-022-01423-x","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T14:03:07Z","timestamp":1674050587000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autoimmunenzephalitis\u00a0\u2013 intensivmedizinische Herausforderungen und Management","Autoimmune encephalitis\u2014Challenges and management in intensive medical care"],"prefix":"10.1007","volume":"94","author":[{"given":"Dirk","family":"Br\u00e4mer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Geis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"9","key":"1423_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau\u00a0J, Graus\u00a0F (2018) Antibody-mediated encephalitis. N\u00a0Engl J Med 378(9):840\u2013851","journal-title":"N Engl J Med"},{"issue":"8","key":"1423_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3949\/ccjm.88a.20122","volume":"88","author":"JR Abbatemarco","year":"2021","unstructured":"Abbatemarco\u00a0JR, Yan\u00a0C, Kunchok\u00a0A et al (2021) Antibody-mediated autoimmune encephalitis: a practical approach. Cleve Clin J Med 88(8):459\u2013471","journal-title":"Cleve Clin J Med"},{"key":"1423_CR3","first-page":"666","volume":"115","author":"KP Wandinger","year":"2018","unstructured":"Wandinger\u00a0KP, Leypoldt\u00a0F, Junker\u00a0R (2018) Autoantibody-mediated encephalitis\u2014differential diagnosis in patients with impaired consciousness of unclear origin. Dtsch Arztebl Int 115:666\u2013673","journal-title":"Dtsch Arztebl Int"},{"key":"1423_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.25131","volume":"83","author":"D Dubey","year":"2018","unstructured":"Dubey\u00a0D, Pittock\u00a0SJ, Kelly\u00a0CR et\u00a0al (2018) Autoimmune encephalitis epidemiology and a\u00a0comparison to infectious encephalitis. Ann Neurol 83:166\u2013177","journal-title":"Ann Neurol"},{"issue":"5","key":"1423_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/practneurol-2020-002567","volume":"21","author":"CE Uy","year":"2021","unstructured":"Uy\u00a0CE, Binks\u00a0S, Irani\u00a0SR (2021) Autoimmune encephalitis: clinical spectrum and management. Pract Neurol 21(5):412\u2013423","journal-title":"Pract Neurol"},{"key":"1423_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12028-015-0196-8","volume":"24","author":"MK Mittal","year":"2016","unstructured":"Mittal\u00a0MK, Rabinstein\u00a0AA, Hocker\u00a0SE et\u00a0al (2016) Autoimmune encephalitis in the ICU: analysis of phenotypes, serologic findings, and outcomes. Neurocrit Care 24:240\u2013250","journal-title":"Neurocrit Care"},{"key":"1423_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1212\/WNL.0000000000001190","volume":"84","author":"TD Singh","year":"2015","unstructured":"Singh\u00a0TD, Fugate\u00a0JE, Rabinstein\u00a0AA (2015) The spectrum of acute encephalitis: causes, management, and predictors of outcome. Neurology 84:359\u2013366","journal-title":"Neurology"},{"key":"1423_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15585","author":"L Schwarz","year":"2022","unstructured":"Schwarz\u00a0L, Akbari\u00a0N, Pr\u00fcss\u00a0H et al (2022) Clinical characteristics, treatments, outcome and prognostic factors of severe autoimmune encephalitis in the intensive care unit: standard treatment and the value of additional plasma cell depleting escalation therapies for treatment-refractory patients. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15585","journal-title":"Eur J Neurol"},{"issue":"20","key":"1423_CR9","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000002125","volume":"85","author":"T Armangue","year":"2015","unstructured":"Armangue\u00a0T, Moris\u00a0G, Cantar\u00edn-Extremera\u00a0V et al (2015) Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology 85(20):1736\u20131743","journal-title":"Neurology"},{"key":"1423_CR10","doi-asserted-by":"publisher","first-page":"2548528","DOI":"10.1155\/2018\/2548528","volume":"2018","author":"S Shah","year":"2018","unstructured":"Shah\u00a0S, Dunn-Pirio\u00a0A, Luedke\u00a0M et al (2018) Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med 2018:2548528. https:\/\/doi.org\/10.1155\/2018\/2548528","journal-title":"Case Rep Neurol Med"},{"issue":"8","key":"1423_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud\u00a0H, Probasco\u00a0J, Irani\u00a0SR et al (2021) Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J\u00a0Neurol Neurosurg Psychiatry 92(8):897\u2013907","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1423_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus\u00a0F, Titulaer\u00a0MJ, Balu\u00a0R et\u00a0al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391\u2013404","journal-title":"Lancet Neurol"},{"issue":"11","key":"1423_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1212\/WNL.0b013e3182698cd8","volume":"79","author":"SE Schmitt","year":"2012","unstructured":"Schmitt\u00a0SE, Pargeon\u00a0K, Frechette\u00a0ES et al (2012) Extreme delta brush: a\u00a0unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79(11):1094\u20131100","journal-title":"Neurology"},{"issue":"4","key":"1423_CR14","first-page":"633","volume":"27","author":"M Gastaldi","year":"2020","unstructured":"Gastaldi\u00a0M, Mariotto\u00a0S, Giannoccaro\u00a0MP et\u00a0al (2020) Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a\u00a0multicenter retrospective study. J\u00a0Neurol 27(4):633\u2013643","journal-title":"J Neurol"},{"key":"1423_CR15","doi-asserted-by":"publisher","first-page":"e1088","DOI":"10.1212\/NXI.0000000000001088","volume":"8","author":"F Thaler","year":"2021","unstructured":"Thaler\u00a0F, Zimmermann\u00a0L, Kammermeier\u00a0S et al (2021) Rituximab treatment and long-term outcome of patients with autoimmune encephalitis real-world evidence from the GENERATE registry. Neurol Neuroimmunol Neuroinflamm 8:e1088","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1423_CR16","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","volume":"13","author":"W-J Lee","year":"2016","unstructured":"Lee\u00a0W\u2011J, Lee\u00a0S\u2011T, Moon\u00a0J et al (2016) Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics 13:824\u2013832","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1423_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","volume":"88","author":"F Scheibe","year":"2017","unstructured":"Scheibe\u00a0F, Pr\u00fcss\u00a0H, Mengel\u00a0AM et al (2017) Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 88(4):366\u2013370","journal-title":"Neurology"},{"issue":"2","key":"1423_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","volume":"267","author":"F Scheibe","year":"2020","unstructured":"Scheibe\u00a0F, Ostendorf\u00a0L, Reincke\u00a0SM et al (2020) Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. J\u00a0Neurol 267(2):317\u2013323","journal-title":"J Neurol"},{"issue":"1","key":"1423_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1186\/s13063-020-04516-7","volume":"21","author":"J Wickel","year":"2020","unstructured":"Wickel\u00a0J, Chung\u00a0HY, Platzer\u00a0S et al (2020) Generate-Boost: study protocol for a\u00a0prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis. Trials 21(1):625","journal-title":"Trials"},{"issue":"2","key":"1423_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer\u00a0MJ, McCracken\u00a0L, Gabilondo\u00a0I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157\u2013165","journal-title":"Lancet Neurol"},{"issue":"1","key":"1423_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.24979","volume":"82","author":"A Gadoth","year":"2017","unstructured":"Gadoth\u00a0A, Pittock\u00a0SJ, Dubey\u00a0D et al (2017) Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients. Ann Neurol 82(1):79\u201392","journal-title":"Ann Neurol"},{"key":"1423_CR22","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1212\/NXI.0000000000000514","volume":"6","author":"J Schubert","year":"2019","unstructured":"Schubert\u00a0J, Br\u00e4mer\u00a0D, Huttner\u00a0HB et\u00a0al (2019) Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm 6:e514\u201310","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1423_CR23","unstructured":"Deutsche Gesellschaft f\u00fcr NeuroIntensiv- und Notfallmedizin (DGNI) https:\/\/www.dgni.de\/. Zugegriffen: Nov. 2022"},{"key":"1423_CR24","unstructured":"DGAI Analgesie (2021) Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie). https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/001-012.html. Zugegriffen: 19. Okt. 2021"},{"issue":"2","key":"1423_CR25","doi-asserted-by":"publisher","first-page":"e233772","DOI":"10.1136\/bcr-2019-233772","volume":"13","author":"C Leding","year":"2020","unstructured":"Leding\u00a0C, Marstrand\u00a0L, Jorgensen\u00a0A (2020) Complete cognitive recovery in a\u00a0severe case of anti-N-methyl-d-aspartate receptor encephalitis treated with electroconvulsive therapy. BMJ Case Rep 13(2):e233772","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1423_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau\u00a0J, Lancaster\u00a0E, Martinez-Hernandez\u00a0E et al (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10(1):63\u201374","journal-title":"Lancet Neurol"},{"issue":"4","key":"1423_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/01.aco.0000174961.90135.dc","volume":"18","author":"C Grasshoff","year":"2005","unstructured":"Grasshoff\u00a0C, Rudolph\u00a0U, Antkowiak\u00a0B (2005) Molecular and systemic mechanisms of general anaesthesia: the \u201emulti-site and multiple mechanisms\u201c concept. Curr Opin Anaesthesiol 18(4):386\u2013391. https:\/\/doi.org\/10.1097\/01.aco.0000174961.90135.dc","journal-title":"Curr Opin Anaesthesiol"},{"issue":"50","key":"1423_CR28","doi-asserted-by":"publisher","first-page":"e13651","DOI":"10.1097\/MD.0000000000013651","volume":"97","author":"N Wada","year":"2018","unstructured":"Wada\u00a0N, Tashima\u00a0K, Motoyasu\u00a0A et al (2018) Anesthesia for patient with anti-N-methyl-D-aspartate receptor encephalitis: a case report with a\u00a0brief review of the literature. Medicine 97(50):e13651","journal-title":"Medicine"},{"key":"1423_CR29","doi-asserted-by":"publisher","first-page":"813174","DOI":"10.3389\/fimmu.2022.813174","volume":"13","author":"R Zhong","year":"2022","unstructured":"Zhong\u00a0R, Zhang\u00a0X, Chen\u00a0Q et\u00a0al (2022) Acute symptomatic seizures and risk of epilepsy in autoimmune encephalitis: a retrospective cohort study. Front Immunol 13:813174","journal-title":"Front Immunol"},{"issue":"3","key":"1423_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","volume":"30","author":"M Spatola","year":"2017","unstructured":"Spatola\u00a0M, Dalmau\u00a0J (2017) Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol 30(3):345\u2013353","journal-title":"Curr Opin Neurol"},{"key":"1423_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2018.09.018","volume":"68","author":"C Sculier","year":"2019","unstructured":"Sculier\u00a0C, Gaspard\u00a0N (2019) New onset refractory status epilepticus (NORSE). Seizure 68:72\u201378. https:\/\/doi.org\/10.1016\/j.seizure.2018.09.018","journal-title":"Seizure"},{"key":"1423_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.seizure.2016.07.002","volume":"41","author":"OD Bakpa","year":"2016","unstructured":"Bakpa\u00a0OD, Reuber\u00a0M, Irani\u00a0SR (2016) Antibody-associated epilepsies: clinical features, evidence for immunotherapies and future research questions. Seizure 41:26\u201341","journal-title":"Seizure"},{"key":"1423_CR33","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"F Rosenow","year":"2020","unstructured":"Rosenow\u00a0F, Weber\u00a0J et al (2020) Status epilepticus im Erwachsenenalter, S2k-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"issue":"3","key":"1423_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12028-021-01250-z","volume":"35","author":"HR Stetefeld","year":"2021","unstructured":"Stetefeld\u00a0HR, Schaal\u00a0A, Scheibe\u00a0F et al (2021) Isoflurane in (super-) refractory status epilepticus: a multicenter evaluation. Neurocrit Care 35(3):631\u2013639","journal-title":"Neurocrit Care"},{"key":"1423_CR35","doi-asserted-by":"publisher","first-page":"624202","DOI":"10.3389\/fneur.2021.624202","volume":"12","author":"KS Husari","year":"2021","unstructured":"Husari\u00a0KS, Cervenka\u00a0MC (2021) Ketogenic diet therapy for the treatment of post-encephalitic and autoimmune-associated epilepsies. Front Neurol 12:624202","journal-title":"Front Neurol"},{"issue":"3","key":"1423_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/epi.13644","volume":"58","author":"D T\u00e9nyi","year":"2017","unstructured":"T\u00e9nyi\u00a0D, Gyimesi\u00a0C, Kup\u00f3\u00a0P et\u00a0al (2017) Ictal asystole: a systematic review. Epilepsia 58(3):356\u2013362","journal-title":"Epilepsia"},{"key":"1423_CR37","unstructured":"Deutsches Netzwerk der Erforschung von autoimmuner Enzephalitis (GENERATE\u2014GErman NEtwork for REsearch on AuToimmune Encephalitis) https:\/\/generate-net.de\/. Zugegriffen: Nov. 2022"},{"key":"1423_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s00063-019-0604-5","volume":"114","author":"A G\u00fcnther","year":"2019","unstructured":"G\u00fcnther\u00a0A, Schubert\u00a0J, Witte\u00a0OW et\u00a0al (2019) Intensivmedizinische Aspekte der Autoimmunenzephalitis. Med Klin Intensivmed Notfmed 114:620\u2013627. https:\/\/doi.org\/10.1007\/s00063-019-0604-5","journal-title":"Med Klin Intensivmed Notfmed"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01423-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-022-01423-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01423-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:07:06Z","timestamp":1675426026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-022-01423-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1007\/s00115-022-01423-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"15 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Geis: Vortragshonorare von Alexion und Roche und Beraterhonorare von Alexion, Roche und Sobi. A.\u00a0G\u00fcnther: Vortrags- und\/oder Beraterhonorare von Ipsen, Boehringer-Ingelheim, Bristol Myers Squibb, Occlutech, Pfizer, Daiichi Sankyo und Merz; Forschungsunterst\u00fctzung durch Ipsen und Merz. Keine der genannten Unterst\u00fctzungen hatten Einfluss auf die Erstellung des Manuskriptes. D. Br\u00e4mer gibt an, dass kein Interessenskonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}